Literature DB >> 6355639

[Hypocalcemia in malignant diseases].

E Heidbreder, K Schafferhans, A Heidland.   

Abstract

Hypercalcemia accompanies often malignant diseases. The majority of cases of malignancy complicated by hypercalcemia is induced by metastases involving bone, hypercalcemia may also accompany localised tumors. Various hormones have been implicated in the genesis of malignant hypercalcemia: ectopic secretion of parathyroid hormone by tumor or orthotopic secretion by concomitant primary hyperparathyroidism, prostaglandin activating osteoclasts, production of hypercalcemic factor other than these hormones. This review summarizes current knowledge about endocrine-mediated mechanisms which produce hypercalcemia and about its frequency and mechanism in different types of tumors.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6355639     DOI: 10.1007/bf01496721

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  102 in total

1.  Calcium clearance as a function of sodium clearance in the dog.

Authors:  M WALSER
Journal:  Am J Physiol       Date:  1961-05

2.  Relationship of bone destruction in skeletal metastases to osteoclast activation and prostaglandins.

Authors:  C S Galasko; A Bennett
Journal:  Nature       Date:  1976-10-07       Impact factor: 49.962

3.  Hyperparathyroidism associated with malignant tumors of nonparathyroid origin.

Authors:  G S Omenn; S I Roth; W H Baker
Journal:  Cancer       Date:  1969-11       Impact factor: 6.860

4.  Indomethacin-responsive hypercalcemia in a patient with renal-cell adenocarcinoma.

Authors:  H D Brereton; P V Halushka; R W Alexander; D M Mason; H R Keiser; V T DeVita
Journal:  N Engl J Med       Date:  1974-06-11       Impact factor: 91.245

5.  Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes.

Authors:  J E Horton; L G Raisz; H A Simmons; J J Oppenheim; S E Mergenhagen
Journal:  Science       Date:  1972-09-01       Impact factor: 47.728

6.  The systemic effects of malignant renal tumours.

Authors:  G D Chisholm; R R Roy
Journal:  Br J Urol       Date:  1971-12

7.  Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups.

Authors:  A F Stewart; R Horst; L J Deftos; E C Cadman; R Lang; A E Broadus
Journal:  N Engl J Med       Date:  1980-12-11       Impact factor: 91.245

8.  Correlation of abnormal immunoglobulin with clinical features of myeloma.

Authors: 
Journal:  Arch Intern Med       Date:  1975-01

9.  Partial purification of osteoclast-activating factor from phytohemagglutinin-stimulated human leukocytes.

Authors:  R A Luben; G R Mundy; C L Trummel; L G Raisz
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

10.  Immunocytoma, cancer and other associations of monoclonal gammopathy: a review of 224 cases.

Authors:  B M Colls; M A Lorier
Journal:  N Z Med J       Date:  1975-10-08
View more
  1 in total

1.  [Hypercalcemias in chronic lymphatic leukemias and other non-Hodgkin's lymphomas].

Authors:  H H Hennemann; J Hastka; E Lengfelder; P Pfiester; K Bonatz
Journal:  Klin Wochenschr       Date:  1987-08-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.